Multicenter randomized controlled trial to evaluate the efficacy and safety of probiotic adjunctive therapy for children with primary hypertension.

Background: Probiotics have emerged as a promising therapeutic strategy for blood pressure control in hypertensive adult patients; however, the efficacy and safety of probiotics in childhood hypertension remain uncertain. Methods: We conducted a multicenter, randomized, double-blind, placebo-control...

Descripción completa

Detalles Bibliográficos
Publicado en:Pediatric Nephrology Vol. 40; no. 12; pp. 3707 - 3716
Autores principales: Bidabadi, Elham, Assadi, Farahnak, Naghshizadian, Rama, Rahmani, Khaled, Safaei-Asl, Afshin, Mazaheri, Mojgan, Azarfar, Anoush, Sadeghi-bojd, Simin, Ghane Sharbaf, Fatemeh, Abbasi, Arash, Badeli, Hamidreza, Eskandarifar, Alireza
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: Springer Nature Dec2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=188853864&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 188853864
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        0931041X
        EF1
      jtl: Pediatric Nephrology
      issn: 0931041X
      maglogo: N
    pubinfo:
      dt: Dec2025
      vid: 40
      iid: 12
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        188853864
        186949007
        188853864
        188853864
        10.1007/s00467-025-06866-3
        188853864
      ppf: 3707
      ppct: 9
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Multicenter randomized controlled trial to evaluate the efficacy and safety of probiotic adjunctive therapy for children with primary hypertension.
      aug:
        au:
          Bidabadi, Elham
          Assadi, Farahnak
          Naghshizadian, Rama
          Rahmani, Khaled
          Safaei-Asl, Afshin
          Mazaheri, Mojgan
          Azarfar, Anoush
          Sadeghi-bojd, Simin
          Ghane Sharbaf, Fatemeh
          Abbasi, Arash
          Badeli, Hamidreza
          Eskandarifar, Alireza
        affil: https://ror.org/04ptbrd12 Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran
      sug:
        subj:
          Hypertension Drug Therapy
          Antihypertensive Agents Therapeutic Use
          Probiotics Therapeutic Use
          Neoadjuvant Therapy
          Drug Efficacy
          Patient Safety
          Human
          Male
          Female
          Child
          Adolescence
          Iran
          United States
          Multicenter Studies
          Double-Blind Studies
          Randomized Controlled Trials
          Random Assignment
          Chi Square Test
          Fisher's Exact Test
          Analysis of Covariance
          Multiple Logistic Regression
          Data Analysis Software
          Blood Pressure Determination
          Medication Compliance
          Descriptive Statistics
          Blood Pressure Drug Effects
          Gut Microbiota Drug Effects
          Hypertension Prevention and Control
          Funding Source
          Child: 6-12 years
          Adolescent: 13-18 years
          Male
          Female
      ab: Background: Probiotics have emerged as a promising therapeutic strategy for blood pressure control in hypertensive adult patients; however, the efficacy and safety of probiotics in childhood hypertension remain uncertain. Methods: We conducted a multicenter, randomized, double-blind, placebo-controlled trial in children with primary hypertension (HTN). Study endpoints included a reduction in absolute systolic or diastolic blood pressure of at least 3.0 mmHg and 2.0 mmHg, respectively, and the incidence of adverse events during the 4-month study period. Results: Sixty-six patients were randomized to receive probiotics plus conventional drugs (study group, n = 33) or antihypertensive drugs alone (control group, n = 33) for 4 months. The study group (probiotics plus antihypertensive drugs, n = 33) and the control group (antihypertensive drugs alone, n = 33) had similar demographics, including age, sex, and body mass index. Most patients had stage-1 HTN (66%). The study group had a larger reduction in systolic and diastolic blood pressure (BP) compared to the control group. The mean change in systolic BP was -4.9 mmHg; 95% confidence interval [CI], − 6.96 to − 2.84 (study group) vs. -3.1 mmHg; 95% CI, − 4.12 to − 2.13 (control group), p = 0.02. For diastolic BP, it was -3.3 mmHg; 95% CI (-4.12 to -2.13) (study group) vs. -2.1 mmHg; 95% CI, -2.50 to -1.82, p = 0.04 (control group), p = 0.04. The reduction in BP was more significant in children with stage-1 HTN compared to those with stage-2 HTN. No serious adverse events (SAEs) were observed during the trial. Conclusions: Probiotics combined with conventional antihypertensive drugs significantly reduced systolic and diastolic BP in children with primary HTN and have an acceptable safety profile. Trial Registration: IRCT20200608047689N3, 07/14/2024, https://irct.behdasht.gov.ir.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N